GlassScriptPhysician profile
Imad Khdair
NPI 1093725624
$2,501.95
in general payments reported to CMS, 2019-2025
32 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $371 · 2021: $595 · 2022: $476 · 2023: $365 · 2024: $190 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.38 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.48 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $284.98 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.83 | 2021-2025 | |
| Abbvie INC. | $177.67 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $155.71 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $147.38 | 2019-2024 | Lokelma, Airsupra |
| Allergan, INC. | $139.44 | 2019-2020 | |
| Dexcom, INC. | $109.36 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $95.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $92.92 | 2021-2025 | Evenity, Prolia, Otezla |
| Otsuka America Pharmaceutical, INC. | $81.10 | 2022-2024 | Rexulti, Nuedexta |
| Corcept Therapeutics | $70.91 | 2025 | Korlym |
| Ardelyx, INC. | $66.79 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $42.95 | 2021 | |
| Astellas Pharma US INC | $41.08 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.71 | 2019-2024 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $37.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.76 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $35.04 | 2022 | |
| Eisai INC. | $33.34 | 2020-2021 | |
| Exact Sciences Corporation | $31.55 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $21.91 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.96 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $20.21 | 2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.11 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.75 | 2021 | |
| Scynexis, INC. | $16.29 | 2022 | |
| Lundbeck LLC | $16.19 | 2023 | Rexulti |
| Shield Therapeutics INC | $15.21 | 2024 | |
| Genentech USA, INC. | $14.52 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.88 | 2021 | |
| Esperion Therapeutics, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Khdair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.